Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.


29 July 2022

CNS quantitative systems biology Masterclass

This is the 4th QSPainRelief Masterclass, held by Robert Carr (CEO) and Athan Spiros, Ph.D., from In Silico Biosciences Inc. (ISB), a biosciences company and QSPainRelief partner located in Lexington, USA, that specializes in computer-based mechanistic modeling of central nervous system (CNS) diseases. The Masterclass was held online due to the pandemic and recorded via Zoom on December 15th, 2021, within the realm of the remote 3rd QSPainRelief General Assembly (GA) Meeting.

More news


26 May 2022

Successful 6th SC Meeting in Munich

The 6th Steering Committee (SC) Meeting was held in Munich, Germany, from 25-24 May 2022. Despite the rainy weather, the SC members and all other attending QSPainRelief researchers and early-career scientists (ECS) enjoyed the science as well as the city. Important issues, such as COVID-19-related delays in the recruitment and start of the clinical study, set-up of the online platform, and data analysis were discussed. The meeting was a full success and the long-awaited first f2f meeting in two years, with some team members participating online via Zoom.

More events
Personalise and maximize pain relief for individuals suffering from chronic pain

Summary Statement

10 institutions in Europe and the USA collaborate for the next 5 years to help patients suffering from chronic pain. QSPainRelief aims to develop effective drug combination treatments for the improved relief of chronic pain. A quantitative systems pharmacology (QSP) mathematical modelling approach will be used to identify and validate more effective therapeutic interventions by smart combinations of existing drugs. The ultimate goal is to personalise and maximize pain relief for individuals suffering from chronic pain while diminishing side effects.

Learn more


  • Consolidating cutting-edge treatment models for chronic pain
  • Summary Statement
  • Validating novel combinational therapies preclinically in vitro and in vivo
  • Conducting clinical studies to detect functional biomarkers
  • Improving the clinical guidelines for pain relief in stratified patient groups
  • Personalising pain relief treatment for each patient
  • Improving the scientific understanding of chronic pain regarding age, sex, disease and genetic factors


  • Novel concepts of combinational pain relief therapies
  • Improved efficacy and acceptability in the clinic
  • Effective stratification of patients with respect to age, sex, disease and genotype
  • Personalised treatment with unswerving benefits for patients
  • Unique knowledge gain and innovation opportunities